Table 3.
COVID-19 hospital admissions and days post-vaccination by age group and vaccination status and type
| Person-years | Number of events | Age-adjusted RRs (95% CI)* | Full-adjusted RRs (95% CI)† | Full and inverse propensity weighting adjusted RRs (95% CI)‡ | Vaccine programme effect (95% CI) | ||
|---|---|---|---|---|---|---|---|
| Vaccinated overall | |||||||
| 18–64 years | |||||||
| Unvaccinated | 66 1 060 | 3442 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 6720 | 18 | 0·40 (0·25 to 0·64) | 0·28 (0·18 to 0·46) | 0·38 (0·29 to 0·50) | 62% (50 to 71) | |
| Vaccine dose 1 (7–13 days)§ | 6667 | 55 | 1·29 (0·99 to 1·69) | 0·88 (0·66 to 1·16) | 1·10 (0·93 to 1·31) | −10% (−31 to 7) | |
| Vaccine dose 1 (14–20 days) | 5458 | 25 | 0·77 (0·52 to 1·14) | 0·49 (0·33 to 0·74) | 0·58 (0·45 to 0·75) | 42% (25 to 55) | |
| Vaccine dose 1 (21–27 days) | 4769 | 12 | 0·43 (0·24 to 0·76) | 0·27 (0·15 to 0·49) | 0·38 (0·27 to 0·54) | 62% (46 to 73) | |
| Vaccine dose 1 (28–34 days) | 3859 | ≤5 | 0·13 (0·04 to 0·41) | 0·09 (0·03 to 0·27) | 0·08 (0·03 to 0·18) | 92% (82 to 97) | |
| Vaccine dose 1 (35–41 days) | 2797 | 7 | 0·43 (0·20 to 0·90) | 0·26 (0·12 to 0·56) | 0·40 (0·25 to 0·62) | 60% (38 to 75) | |
| Vaccine dose 1 (42+ days) | 5166 | 11 | 0·37 (0·20 to 0·66) | 0·24 (0·13 to 0·45) | 0·35 (0·24 to 0·51) | 65% (49 to 76) | |
| 65–79 years | |||||||
| Unvaccinated | 132 254 | 2449 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 9598 | 42 | 0·23 (0·17 to 0·31) | 0·26 (0·19 to 0·35) | 0·12 (0·08 to 0·17) | 88% (83 to 92) | |
| Vaccine dose 1 (7–13 days)§ | 9148 | 75 | 0·44 (0·35 to 0·55) | 0·64 (0·50 to 0·82) | 0·26 (0·20 to 0·35) | 74% (65 to 80) | |
| Vaccine dose 1 (14–20 days) | 4219 | 40 | 0·46 (0·34 to 0·63) | 0·60 (0·43 to 0·83) | 0·25 (0·17 to 0·36) | 75% (64 to 83) | |
| Vaccine dose 1 (21–27 days) | 1179 | 15 | 0·56 (0·34 to 0·94) | 0·47 (0·28 to 0·79) | 0·21 (0·11 to 0·39) | 79% (61 to 89) | |
| Vaccine dose 1 (28–34 days) | 498 | ≤5 | 0·28 (0·09 to 0·86) | 0·16 (0·05 to 0·50) | 0·07 (0·02 to 0·27) | 93% (73 to 98) | |
| Vaccine dose 1 (35–41 days) | 242 | 5 | 1·03 (0·43 to 2·48) | 0·36 (0·14 to 0·91) | 0·16 (0·05 to 0·49) | 84% (51 to 95) | |
| Vaccine dose 1 (42+ days) | 334 | 11 | 1·82 (1·00 to 3·28) | 0·62 (0·34 to 1·15) | 0·28 (0·13 to 0·58) | 72% (42 to 87) | |
| ≥80 years | |||||||
| Unvaccinated | 38 439 | 1807 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 3072 | 96 | 0·68 (0·55 to 0·83) | 0·44 (0·36 to 0·55) | 0·26 (0·20 to 0·32) | 74% (68 to 80) | |
| Vaccine dose 1 (7–13 days)§ | 3876 | 128 | 0·73 (0·61 to 0·88) | 0·63 (0·52 to 0·77) | 0·34 (0·27 to 0·41) | 66% (59 to 73) | |
| Vaccine dose 1 (14–20 days) | 3749 | 89 | 0·53 (0·43 to 0·65) | 0·54 (0·43 to 0·68) | 0·31 (0·24 to 0·39) | 69% (61 to 76) | |
| Vaccine dose 1 (21–27 days) | 3172 | 45 | 0·32 (0·23 to 0·42) | 0·35 (0·26 to 0·49) | 0·21 (0·15 to 0·30) | 79% (70 to 85) | |
| Vaccine dose 1 (28–34 days) | 1894 | 24 | 0·28 (0·18 to 0·41) | 0·30 (0·19 to 0·46) | 0·17 (0·11 to 0·28) | 83% (72 to 89) | |
| Vaccine dose 1 (35–41 days) | 782 | 9 | 0·24 (0·13 to 0·47) | 0·21 (0·11 to 0·41) | 0·13 (0·06 to 0·27) | 87% (73 to 94) | |
| Vaccine dose 1 (42+ days) | 548 | 10 | 0·37 (0·20 to 0·69) | 0·24 (0·13 to 0·46) | 0·15 (0·07 to 0·32) | 85% (68 to 93) | |
| BNT162b2 (Pfizer–BioNTech) | |||||||
| 18–64 years | |||||||
| Unvaccinated | 642 027 | 3277 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 5157 | 9 | 0·28 (0·14 to 0·53) | 0·18 (0·09 to 0·36) | 0·22 (0·15 to 0·34) | 78% (66 to 85) | |
| Vaccine dose 1 (7–13 days)§ | 5757 | 46 | 1·30 (0·97 to 1·73) | 0·84 (0·62 to 1·14) | 1·06 (0·88 to 1·27) | −6% (−27 to 12) | |
| Vaccine dose 1 (14–20 days) | 5141 | 24 | 0·79 (0·53 to 1·19) | 0·49 (0·32 to 0·74) | 0·58 (0·44 to 0·75) | 42% (25 to 56) | |
| Vaccine dose 1 (21–27 days) | 4663 | 12 | 0·44 (0·25 to 0·78) | 0·27 (0·15 to 0·48) | 0·37 (0·26 to 0·53) | 63% (47 to 74) | |
| Vaccine dose 1 (28–34 days) | 3804 | ≤5 | 0·14 (0·04 to 0·42) | 0·08 (0·03 to 0·27) | 0·08 (0·03 to 0·18) | 92% (82 to 97) | |
| Vaccine dose 1 (35–41 days) | 2773 | 7 | 0·43 (0·21 to 0·91) | 0·25 (0·11 to 0·54) | 0·37 (0·24 to 0·59) | 63% (41 to 76) | |
| Vaccine dose 1 (42+ days) | 5161 | 11 | 0·37 (0·20 to 0·67) | 0·23 (0·12 to 0·42) | 0·32 (0·22 to 0·47) | 68% (53 to 78) | |
| 65–79 years | |||||||
| Unvaccinated | 76 418 | 1994 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 4487 | 13 | 0·11 (0·07 to 0·19) | 0·12 (0·07 to 0·20) | 0·07 (0·03 to 0·13) | 93% (87 to 97) | |
| Vaccine dose 1 (7–13 days)§ | 4580 | 39 | 0·33 (0·24 to 0·46) | 0·42 (0·30 to 0·58) | 0·23 (0·15 to 0·34) | 77% (66 to 85) | |
| Vaccine dose 1 (14–20 days) | 1904 | 21 | 0·38 (0·25 to 0·59) | 0·36 (0·23 to 0·56) | 0·20 (0·12 to 0·34) | 80% (66 to 88) | |
| Vaccine dose 1 (21–27 days) | 399 | 5 | 0·40 (0·17 to 0·97) | 0·14 (0·06 to 0·36) | 0·09 (0·03 to 0·27) | 91% (73 to 97) | |
| Vaccine dose 1 (28–34 days) | 278 | ≤5 | 0·36 (0·11 to 1·10) | 0·12 (0·04 to 0·36) | 0·07 (0·02 to 0·27) | 93% (73 to 98) | |
| Vaccine dose 1 (35–41 days) | 188 | 5 | 0·91 (0·38 to 2·20) | 0·23 (0·09 to 0·58) | 0·14 (0·05 to 0·43) | 86% (57 to 95) | |
| Vaccine dose 1 (42+ days) | 329 | 11 | 1·20 (0·66 to 2·17) | 0·38 (0·21 to 0·71) | 0·24 (0·12 to 0·50) | 76% (50 to 88) | |
| ≥80 years | |||||||
| Unvaccinated | 15 963 | 1400 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 497 | 12 | 0·27 (0·16 to 0·48) | 0·14 (0·08 to 0·24) | 0·11 (0·06 to 0·21) | 89% (79 to 94) | |
| Vaccine dose 1 (7–13 days)§ | 654 | 34 | 0·60 (0·43 to 0·85) | 0·28 (0·20 to 0·40) | 0·18 (0·12 to 0·27) | 82% (73 to 88) | |
| Vaccine dose 1 (14–20 days) | 640 | 26 | 0·47 (0·32 to 0·70) | 0·25 (0·17 to 0·37) | 0·15 (0·10 to 0·24) | 85% (76 to 90) | |
| Vaccine dose 1 (21–27 days) | 611 | 21 | 0·40 (0·26 to 0·62) | 0·23 (0·15 to 0·36) | 0·15 (0·09 to 0·25) | 85% (75 to 91) | |
| Vaccine dose 1 (28–34 days) | 503 | 13 | 0·30 (0·17 to 0·52) | 0·19 (0·11 to 0·34) | 0·12 (0·06 to 0·24) | 88% (76 to 94) | |
| Vaccine dose 1 (35–41 days) | 331 | 8 | 0·28 (0·14 to 0·56) | 0·18 (0·09 to 0·38) | 0·13 (0·06 to 0·30) | 87% (70 to 94) | |
| Vaccine dose 1 (42+ days) | 506 | 9 | 0·21 (0·11 to 0·40) | 0·22 (0·11 to 0·43) | 0·15 (0·07 to 0·34) | 85% (66 to 93) | |
| ChAdOx1 (Oxford–AstraZeneca) | |||||||
| 18–64 years | |||||||
| Unvaccinated | 626 849 | 3293 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 1473 | 9 | 0·72 (0·37 to 1·39) | 0·52 (0·26 to 1·02) | 0·82 (0·56 to 1·20) | 18% (−20 to 44) | |
| Vaccine dose 1 (7–13 days)§ | 910 | 9 | 1·20 (0·62 to 2·30) | 0·81 (0·41 to 1·58) | 0·99 (0·64 to 1·52) | 1% (−52 to 36) | |
| Vaccine dose 1 (14–20 days) | 317 | ≤5 | 0·40 (0·06 to 2·87) | 0·28 (0·04 to 2·03) | 0·25 (0·06 to 1·06) | 75% (−6 to 94) | |
| Vaccine dose 1 (21–27 days) | 105 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| Vaccine dose 1 (28–34 days) | 55 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| Vaccine dose 1 (35–41 days) | 24 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| Vaccine dose 1 (42+ days) | 5 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| 65–79 years | |||||||
| Unvaccinated | 81 523 | 2194 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 4761 | 29 | 0·22 (0·15 to 0·32) | 0·24 (0·16 to 0·35) | 0·12 (0·08 to 0·19) | 88% (81 to 92) | |
| Vaccine dose 1 (7–13 days)§ | 4567 | 36 | 0·28 (0·20 to 0·39) | 0·45 (0·31 to 0·63) | 0·21 (0·14 to 0·31) | 79% (69 to 86) | |
| Vaccine dose 1 (14–20 days) | 2316 | 19 | 0·28 (0·18 to 0·44) | 0·46 (0·29 to 0·74) | 0·21 (0·12 to 0·37) | 79% (63 to 88) | |
| Vaccine dose 1 (21–27 days) | 780 | 10 | 0·42 (0·22 to 0·78) | 0·69 (0·37 to 1·32) | 0·32 (0·15 to 0·69) | 68% (31 to 85) | |
| Vaccine dose 1 (28–34 days) | 220 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| Vaccine dose 1 (35–41 days) | 55 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| Vaccine dose 1 (42+ days) | 5 | 0 | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 0·00 (0·00 to NA) | 100% (NA to 100) | |
| ≥80 years | |||||||
| Unvaccinated | 35 266 | 1765 | 1 (ref) | 1 (ref) | 1 (ref) | 0 | |
| Vaccine dose 1 (0–6 days)§ | 2493 | 84 | 0·69 (0·56 to 0·86) | 0·50 (0·40 to 0·63) | 0·28 (0·22 to 0·36) | 72% (64 to 78) | |
| Vaccine dose 1 (7–13 days)§ | 3221 | 94 | 0·61 (0·50 to 0·75) | 0·64 (0·51 to 0·81) | 0·37 (0·29 to 0·47) | 63% (53 to 71) | |
| Vaccine dose 1 (14–20 days) | 3109 | 63 | 0·43 (0·33 to 0·55) | 0·56 (0·42 to 0·74) | 0·37 (0·28 to 0·50) | 63% (50 to 72) | |
| Vaccine dose 1 (21–27 days) | 2561 | 24 | 0·20 (0·13 to 0·29) | 0·30 (0·19 to 0·47) | 0·23 (0·14 to 0·37) | 77% (63 to 86) | |
| Vaccine dose 1 (28–34 days) | 1391 | 11 | 0·16 (0·09 to 0·30) | 0·26 (0·14 to 0·50) | 0·19 (0·09 to 0·40) | 81% (60 to 91) | |
| Vaccine dose 1 (35–41 days) | 451 | ≤5 | 0·04 (0·01 to 0·32) | 0·07 (0·01 to 0·53) | 0·05 (0·00 to 0·56) | 95% (44 to 100) | |
| Vaccine dose 1 (42+ days) | 42 | ≤5 | 0·48 (0·07 to 3·39) | 0·84 (0·12 to 6·03) | 0·64 (0·07 to 6·24) | 36% (−524 to 93) | |
Poisson regression was used to provide all adjusted estimates. Individuals who had previously tested positive were excluded. RR=rate ratios. NA=not applicable. rtPCR=real-time reverse-transcription-PCR.
*
Adjusted for age.
†
Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, and number of underlying medical conditions.
‡
Adjusted for time (in weeks), age, sex, Scottish Index of Multiple Deprivation, number of rtPCR tests before vaccination, number of underlying medical conditions, and inverse propensity of being vaccinated.
§
Any effects observed in less than 14 days are mainly due to vaccine programme effects.